
|Articles|April 22, 2015
- Melanoma (Issue 4)
- Volume 4
- Issue 1
Toxicity of Immunotherapies in Melanoma
Author(s)Jeffrey S. Weber, MD, PhD
Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.
Advertisement
Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.
<<<
Articles in this issue
over 10 years ago
Comparing Two Doses of Ipilimumabover 10 years ago
New Standards Needed to Lessen Surgery Delays in Melanomaover 10 years ago
Gene Removal May Pose Future Treatment in Advanced Melanomaover 10 years ago
The Development of T-VEC for Melanomaover 10 years ago
The Role of Macrophages in BRAF Inhibitor ResistanceAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
5








































